Impaired interleukin-2 (IL-2) production was reported in systemic lupus erythematosus (SLE). The aim of this study was to investigate the clinical relevance of serum IL-2 and therapeutic effects of recombinant IL-2 (rIL-2) in SLE, especially in lupus nephritis (LN). Decreased serum IL-2 was found in patients with active LN (P = 0.014) and correlated with 24-h urine protein excretion (r = −0.281, P = 0.026). Compared with LN patients with decreased levels of serum IL-2, patients with increased levels had better remission rate (P = 0.041). Furthermore, patients with exogenous low-dose IL-2 supplement demonstrated better improved nephritis and higher remission rate (55.56%, P = 0.058) than those with conventional therapy. In addition, the percentages of regulator T (Treg) cells expanded in LN patients with low-dose recombinant human IL-2 treatment (P = 0.007), especially in LN patients achieving remission (P = 0.010). IL-2 deficiency is associated with renal impairment that can be improved by exogenous IL-2 supplement.
Color images are available online.
Get full access to this article
View all access options for this article.
References
1.
AfeltraA, GiganteA, MargiottaDP, TaffonC, CianciR, BarbanoB, LiberatoriM, AmorosoA, Rossi FanelliF. 2015. The involvement of T regulatory lymphocytes in a cohort of lupus nephritis patients: a pilot study. Intern Emerg Med, 10(6):677–683.
2.
ArellanoB, GraberDJ, SentmanCL. 2016. Regulatory T cell-based therapies for autoimmunity. Discov Med, 22(119):73–80.
3.
ComteD, KarampetsouMP, Kis-TothK, YoshidaN, BradleySJ, KyttarisVC, TsokosGC. 2017. Brief report: CD4+ T cells from patients with systemic lupus erythematosus respond poorly to exogenous interleukin-2. Arthritis Rheumatol, 69(4):808–813.
4.
CrispínJC, OukkaM, BaylissG, CohenRA, Van BeekCA, StillmanIE, KyttarisVC, JuangYT, TsokosGC. 2008. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol, 181(12):8761–8766.
5.
DavidsonA.2016. What is damaging the kidney in lupus nephritis?. Nat Rev Rheumatol, 12(3):143–153.
6.
DavidsonTS, DiPaoloRJ, AnderssonJ, ShevachEM. 2007. Cutting edge: IL-2 is essential for TGF-β-mediated induction of Foxp3 T regulatory cells. J Immunol, 178(7):4022–4026.
7.
FontenotJD, RasmussenJP, GavinMA, RudenskyAY. 2005. A function for interleukin-2 in Foxp3-expressing regulatory T cells. Nat Immunol, 6(11):1142–1151.
HochbergMC.1997. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheumatol, 40(9):1725.
10.
HumrichJY, MorbachH, UndeutschR, EnghardP, RosenbergerS, WeigertO, KlokeL, HeimannJ, GaberT, BrandenburgS, ScheffoldA, HuehnJ, RadbruchA, BurmesterGR, RiemekastenG. 2010. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proceedings of the National Academy of Sciences of the United States of America, 107(1):204–209.
11.
IwataY, FuruichiK, KanekoS, WadaT. 2011. The role of cytokine in lupus nephritis. J Biomed Biotechnol, 2011:594809.
12.
KogaT, IchinoseK, TsokosGC. 2017. T cells and IL-17 in lupus nephritis. Clin Immunol, 185:95–99.
13.
KrebsCF, SchmidtT, RiedelJH, PanzerU. 2017. T helper type 17 cells in immune-mediated glomerular disease. Nat Rev Nephrol, 13(10):647–659.
14.
MalekTR.2008. The biology of interleukin-2. Annu Rev Immunol, 26:453–479.
15.
MaloyKJ, PowrieF. 2001. Regulatory T cells in the control of immune pathology. Nat Immunol, 2(9):816–822.
16.
MizuiM, KogaT, LiebermanLA, BeltranJ, YoshidaN, JohnsonMC, TischR, TsokosGC. 2014. Interleukin-2 protects lupus-prone mice from multiple end organ damage by limiting CD4-CD8- interleukin-17 producing T cells. J Immunol, 193(5):2168–2177.
17.
RajagopalanS, ZordanT, TsokosGC, DattaSK. 1990. Pathogenic anti-DNA autoantibody- inducing T helper cell lines from patients with active lupus nephritis: isolation of CD4-8- T helper cell lines that express the gamma delta T-cell antigen receptor. Proc Natl Acad Sci U S A, 87(18):7020–7024.
18.
RayJP, StaronMM, ShyerJA, HoPC, MarshallHD, GraySM, LaidlawBJ, ArakiK, AhmedR. 2015. The interleukin-2-mTORc1 kinase axis defines the signaling, differentiation, and metabolism of T helper 1 and follicular B helper T cells. Immunity, 43(4):690–702.
19.
SakaguchiS.2005. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol, 6(4):345–352.
20.
Suárez-FueyoA, BradleySJ, KlatzmannD, TsokosGC. 2017. T cells and autoimmune kidney disease. Nat Rev Nephrol, 13(6):329–343.
21.
TseliosK, SarantopoulosA, GkougkourelasI, PapagianniA, BouraP. 2014. Increase of peripheral T regulatory cells during remission induction with cyclophosphamide in active systemic lupus erythematosus. Int J Rheum Dis, 17(7):790–795.
22.
TsokosGC.2011. Systemic lupus erythematosus. N Engl J Med, 365(22):2110–2121.
23.
von BoehmerH, DanielC. 2013. Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nat Rev Drug Discov, 12(1):51–63.
24.
von Spee-MayerC, SiegertE, AbdiramaD, RoseA, KlausA, AlexanderT, EnghardP, SawitzkiB, HiepeF, RadbruchA, BurmesterGR, RiemekastenG, HumrichJY. 2016. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis, 75(7):1407–1415.
25.
XingQ, WangB, SuH, CuiJ, LiJ. 2012. Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis. Rheumatol Int, 32(4):949–958.
26.
YanJ, JambaldorjE, LeeJG, JangJY, ShimJM, HanM, KooTY, AhnC, YangJ. 2016. Granulocyte colony-stimulating factor treatment ameliorates lupus nephritis through the expansion of regulatory T cells. BMC Nephrol, 17(1):175.
27.
YanJJ, LeeJG, JangJY, KooTY, AhnC, YangJ. 2017. IL-2/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4+CD25+Foxp3+ regulatory T cells. Kidney Int, 91(3):603–615.
28.
YinS, MaoY, LiX, YueC, ZhouC, HuangL, MoW, LiangD, ZhangJ, HeW, ZhangX. 2015. Hyperactivation and in situ recruitment of inflammatory Vδ2 T cells contributes to disease pathogenesis in systemic lupus erythematosus. Sci Rep, 5:14432.
29.
ZhangRJ, ZhangX, ChenJ, ShaoM, YangY, BalaubramaniamB, SunXL, AmbrusJLJr., HeJ, LiZG.2018. Serum soluble CD25 as a risk factor of renal impairment in systemic lupus erythematosus—a prospective cohort study. Lupus, 27(7):1100–1106.
30.
ZhengSG, WangJ, WangP, GrayJD, HorwitzDA. 2007. IL-2 is essential for TGF-β to convert naive CD4+CD25− cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol, 178(4):2018–2027.
